These findings suggest that when PSMA-PET is performed to restage PCa patients, the results of PSMA-PET is a prognostic parameter for oncologic outcomes, helping the treating physicians to guide salvage therapies, but also to adopt a more conservative approach in the case of a negative scan [24]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.